Edition:
United States

GlaxoSmithKline PLC (GSK.F)

GSK.F on Frankfurt Stock Exchange

19.17EUR
24 May 2017
Change (% chg)

-- (--)
Prev Close
€19.17
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
25,080
52-wk High
€20.57
52-wk Low
€16.92

Latest Key Developments (Source: Significant Developments)

Kuehne und Nagel and GlaxoSmithKline expand partnership with new UK domestic distribution contract
Wednesday, 17 May 2017 11:37am EDT 

May 17 (Reuters) - KUEHNE UND NAGEL INTERNATIONAL AG :KUEHNE + NAGEL AND GLAXOSMITHKLINE EXPAND PARTNERSHIP WITH NEW UK DOMESTIC DISTRIBUTION CONTRACT.  Full Article

Paulson & Co Inc takes share stake in Amazon, Arconic - SEC filing
Monday, 15 May 2017 05:33pm EDT 

May 15 (Reuters) - Paulson & Co Inc : :Paulson & Co Inc takes share stake in Amazon of 5,500 shares - SEC filing.Paulson & Co Inc takes share stake of 983,300 shares in Arconic Inc.Paulson & Co Inc takes share stake of 78,101 shares in Sarepta Therapeutics Inc.Paulson & Co Inc ups share stake in Glaxosmithkline PLC by 40.2 percent to 415,100 Sponsored ADR.Paulson & Co Inc - Change in holdings are as of March 31, 2017 and compared with the previous quarter ended as of Dec 31, 2016.  Full Article

Ionis Pharma announces Phase 3 NEURO-TTR study of inotersen meets both primary endpoints
Monday, 15 May 2017 07:00am EDT 

May 15 (Reuters) - Ionis Pharmaceuticals Inc :Ionis pharmaceuticals announces phase 3 neuro-ttr study of inotersen (ionis-ttr rx) meets both primary endpoints.Says statistically significant differences were also observed for both endpoints at eight months.Ionis pharmaceuticals - long-term safety and efficacy data with inotersen currently being collected in open-label extension of phase 3 neuro-ttr study.Says review of full data package from neuro-ttr study by ionis and gsk is ongoing.Says preparation of regulatory marketing applications for inotersen is underway.Ionis pharmaceuticals - gsk has option to license inotersen following review of additional data and prior to submission of regulatory applications.  Full Article

GlaxoSmithKline announces positive results for asthma drug study
Friday, 5 May 2017 07:38am EDT 

May 5 (Reuters) - Glaxosmithkline Plc ::Announced positive results from innovative Salford Lung Study (SLS) in asthma.Relvar Ellipta significantly improved asthma control in Salford Lung Study patients compared with their usual care.Study showed significantly more asthma patients initiated on treatment with Relvar Ellipta achieved improvement in their asthma control.At 24 weeks a significantly higher percentage of patients with asthma achieved better control of their asthma (71 pct) measured by asthma control test (ACT).Statistically significant findings were also seen at 12, 40 and 52 weeks.Serious adverse events of pneumonia by randomised group were reported by 39 patients (ff/vi arm 23, 1 pct; usual care arm 16, <1 pct).  Full Article

Epizyme Earns $10 million milestone payment from Glaxosmithkline
Thursday, 4 May 2017 06:30am EDT 

May 4 (Reuters) - Epizyme Inc : :Epizyme earns $10 million milestone payment from glaxosmithkline for initiation of GLP Toxicology studies with novel methyltransferase inhibitor.Epizyme - milestone payment follows GSK'S initiation of GLP toxicology studies for methyltransferase inhibitor discovered by co, licensed to GSK.  Full Article

Bluebird Bio enters into patent license agreement with Glaxosmithkline for commercialization of Gene Therapies
Tuesday, 2 May 2017 08:00am EDT 

May 2 (Reuters) - Bluebird Bio Inc :Bluebird bio enters lentiviral vector patent license agreement with Glaxosmithkline for commercialization of gene therapies.Bluebird bio - under terms of agreement, gsk will non-exclusively license certain bluebird patent rights related to lentiviral vector technology.Bluebird bio- financial terms of agreement include an upfront payment to bluebird as well as potential development and regulatory milestone payments.Bluebird bio inc - financial terms of agreement also include low single digit royalties on net sales of covered products.  Full Article

GSK still in talks with AstraZeneca about start date for Luke Miels
Wednesday, 26 Apr 2017 10:26am EDT 

April 26 (Reuters) - GlaxoSmithKline Plc CEO Emma Walmsley told analysts::"no comment" on whether would launch authorised advair generic in u.s..still in discussion with AstraZeneca about date for Luke Miels to join GSK.  Full Article

New GSK plans to sharpen priorities in drug development
Wednesday, 26 Apr 2017 07:01am EDT 

April 26 (Reuters) - GlaxoSmithKline CEO Emma Walmsley told reporters::still lot of uncertainty around generic Advair.focus now on execution, since next wave of new drug launches is in early 2020s.priority in short term is focusing on opportunities with new drug launches, including Shingrix and closed triple.long term priority must be around strengthening pharma pipeline.need to make tough choices around allocation of capital in pharma.sees logic and benefit in having broad company with 3 business units.all 3 businesses must continue to perform competitively and gsk must remain best owner.still digesting Novartis transaction but watching opportunities for M&A.M&A most likely to bolster early-stage drug pipeline.wants bigger returns from pharma research and development investment.wants to bring commercial voice in much earlier in drug development.wants fewer but bigger drug launches in future.will need to switch off some areas of drug development.  Full Article

GSK seeks Japanese approval for shingles vaccine
Tuesday, 18 Apr 2017 04:16am EDT 

April 18 (Reuters) - GlaxoSmithKline Plc ::Gsk vaccine submission for shingles in japan.JV between GSK, Daiichi Sankyo submitted new drug application in Japan seeking approval for candidate shingles vaccine, shingrix.  Full Article

GSK makes changes to financial reporting; sees growth in emerging markets
Tuesday, 11 Apr 2017 07:02am EDT 

GlaxoSmithKline Plc : Change to financial reporting framework . As a result of its latest review, GSK will be making following change to its financial reporting from Q1 2017. . Core results will be renamed adjusted results and will include 'ordinary course' legal charges . From Q1 2017, only significant legal charges and expenses will be excluded in order to present adjusted results. . Change is not expected to affect group's previously announced guidance for 2017 or group's outlook for five-year period 2016-2020 . Target expectation of at least 6 bln stg of revenue/ year on a CER basis by 2020 from products launched since 2013 is now expected to be met up to 2 yrs earlier .Expects volume demand for its products to increase, particularly in emerging markets.  Full Article

More From Around the Web

BRIEF-Kuehne und Nagel and GlaxoSmithKline expand partnership with new UK domestic distribution contract

* KUEHNE + NAGEL AND GLAXOSMITHKLINE EXPAND PARTNERSHIP WITH NEW UK DOMESTIC DISTRIBUTION CONTRACT Source text for Eikon: Further company coverage: (Gdynia Newsroom)